Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future

被引：64
作者：
Boeckh, Michael [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
来源：
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2011年
基金：
美国国家卫生研究院;
关键词：
CELL TRANSPLANT RECIPIENTS; CYTOMEGALOVIRUS-INFECTION; DOUBLE-BLIND; MARIBAVIR PROPHYLAXIS; PP65; ANTIGENEMIA; DISEASE; GANCICLOVIR; IMPACT; DONOR; RISK;
D O I：
10.1182/asheducation-2011.1.305
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
Although major progress has been made in the prevention of CMV disease after hematopoietic cell transplantation (HCT), specific problems remain and available antiviral agents are associated with major toxicities. This article reviews current aspects of CMV diagnosis, prevention, and treatment in HCT recipients and defines areas of unmet medical need.
引用
收藏
页码：305 / 309
页数：5
相关论文
共 40 条
  • [1] Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients
    Avery, R. K.
    Marty, F. M.
    Strasfeld, L.
    Lee, I.
    Arrieta, A.
    Chou, S.
    Tatarowicz, W.
    Villano, S.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (06) : 489 - 496
  • [2] The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
    Boeckh, M
    Nichols, WG
    [J]. BLOOD, 2004, 103 (06) : 2003 - 2008
  • [3] Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies
    Boeckh, M
    Nichols, WG
    Papanicolaou, G
    Rubin, R
    Wingard, JR
    Zaia, Y
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (09) : 543 - 558
  • [4] Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
    Boeckh, M
    Leisenring, W
    Riddell, SR
    Bowden, RA
    Huang, ML
    Myerson, D
    Stevens-Ayers, T
    Flowers, MED
    Cunningham, T
    Corey, L
    [J]. BLOOD, 2003, 101 (02) : 407 - 414
  • [5] Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
    Boeckh, M
    Gooley, TA
    Myerson, D
    Cunningham, T
    Schoch, G
    Bowden, RA
    [J]. BLOOD, 1996, 88 (10) : 4063 - 4071
  • [6] Cytomegalovirus: pathogen, paradigm, and puzzle
    Boeckh, Michael
    Geballe, Adam P.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (05) : 1673 - 1680
  • [7] How I treat cytomegalovirus in hematopoietic cell transplant recipients
    Boeckh, Michael
    Ljungman, Per
    [J]. BLOOD, 2009, 113 (23) : 5711 - 5719
  • [8] Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir
    Chou, Sunwen
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2008, 18 (04) : 233 - 246
  • [9] Immunobiology of Human Cytomegalovirus: from Bench to Bedside
    Crough, Tania
    Khanna, Rajiv
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2009, 22 (01) : 76 - +
  • [10] Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation
    Einsele, H
    Reusser, P
    Bornhäuser, M
    Kalhs, P
    Ehninger, G
    Hebart, H
    Chalandon, Y
    Kröger, N
    Hertenstein, B
    Rohde, F
    [J]. BLOOD, 2006, 107 (07) : 3002 - 3008
1234